tldrdaily.news logo
Tag

Benralizumab

All articles tagged with #benralizumab

health1 year ago

Breakthrough Asthma and COPD Therapy Emerges After 50 Years

A new clinical trial has shown that the antibody drug benralizumab can significantly reduce asthma and COPD flare-ups, outperforming standard steroid treatments. Conducted by scientists in the UK, Australia, and Sweden, the trial found that patients receiving benralizumab experienced fewer treatment failures and hospital visits. Benralizumab, developed by AstraZeneca, targets eosinophils, white blood cells that contribute to asthma and COPD symptoms. The findings suggest benralizumab could become the first new treatment for these conditions in 50 years, pending further large-scale studies.

via Gizmodo|
#asthma#astrazeneca#benralizumab
health1 year ago

Breakthrough Asthma and COPD Drug Emerges After 50 Years

A new study published in The Lancet Respiratory Medicine reveals that benralizumab, a monoclonal antibody, may be a breakthrough treatment for asthma and COPD flare-ups, offering a safer alternative to steroids like prednisolone. The trial showed that benralizumab significantly reduced treatment failure rates and improved patient outcomes, with fewer side effects compared to steroids. While benralizumab is already used for long-term asthma management, further phase 3 trials are needed to approve its use during flare-ups.

via ScienceAlert|
#asthma#benralizumab#copd
health1 year ago

Breakthrough Asthma and COPD Treatment Emerges After 50 Years

British scientists have tested a new treatment for asthma attacks and COPD, marking the first advancement in 50 years. The drug, benralizumab, is a monoclonal antibody that targets eosinophils to reduce lung inflammation and has shown to be more effective than traditional steroid tablets, reducing the need for further treatment by 30%. This could be a significant breakthrough for millions suffering from these conditions, as the treatment has fewer side effects and can potentially be administered at home.

via Good News Network|
#asthma#benralizumab#copd
health1 year ago

Revolutionary Injectable Asthma Treatment Marks First Breakthrough in 50 Years

A new clinical trial has shown that benralizumab, a monoclonal antibody, is more effective than steroids in reducing symptoms of asthma and COPD flare-ups. The drug, already approved for severe asthma, targets eosinophils, white blood cells that cause lung inflammation. Participants in the trial experienced fewer attacks and improved quality of life compared to those on steroids. This development could revolutionize treatment for asthma and COPD, which have seen little change in treatment options over the past fifty years.

via Newsmax|
#asthma#benralizumab#clinical-trial
health1 year ago

Revolutionary Asthma Treatment Emerges After 50 Years

Researchers at King's College London have discovered a new treatment for asthma attacks, marking the first advancement in 50 years. The drug, benralizumab, targets eosinophils, a type of white blood cell involved in inflammation, and has shown promise in reducing treatment failure rates compared to steroids. While not yet ready for widespread use, the drug could potentially revolutionize care for asthma and COPD patients, pending further trials. Participants in the study reported fewer side effects and improved quality of life.

via BBC.com|
#asthma#benralizumab#copd
health1 year ago

Revolutionary Asthma Treatment Emerges After 50 Years

A new treatment using the monoclonal antibody benralizumab has shown significant promise in managing severe asthma and COPD attacks, marking the first major breakthrough in 50 years. The treatment, which involves a higher single dose injection during flare-ups, was found to be more effective than traditional steroid tablets, reducing the need for further treatment by 30% and improving patients' quality of life. This advancement could transform care for millions worldwide, offering a safer alternative with fewer side effects than steroids.

via The Guardian|
#asthma#benralizumab#copd
health2 years ago

Breakthrough Antibody Therapy Effectively Treats Severe Asthma in 92% of Cases

A landmark clinical trial funded by AstraZeneca has found that benralizumab, a monoclonal antibody treatment, can significantly reduce the need for high-dose steroid treatments in patients with severe eosinophilic asthma. The study showed that 92% of patients safely reduced their use of inhaled steroids, with over 60% no longer needing them at all. Benralizumab works by targeting and reducing inflammation-causing immune cells called eosinophils. However, the researchers caution that these results only apply to a specific type of asthma, and patients who do not respond as well to benralizumab may still require intensive steroid treatments.

via ScienceAlert|
#antibody-therapy#asthma#benralizumab